The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications
- 1 January 2016
- journal article
- review article
- Published by Elsevier BV in American Heart Journal
- Vol. 171 (1), 82-91
- https://doi.org/10.1016/j.ahj.2015.08.021
Abstract
No abstract availableFunding Information
- Boehringer Ingelheim
- Novartis
- Deutsche Gesellschaft für Kardiologie-Herz und Kreislaufforschung.
- Medtronic
- Servier
- Pfizer
- Deutsche Hochdruckliga
- Bayer
- St. Jude Medical
This publication has 52 references indexed in Scilit:
- Renal sympathetic denervation as second‐line therapy in mild resistant hypertension: A pilot studyCatheterization and Cardiovascular Interventions, 2012
- Prevalence of Resistant Hypertension in the United States, 2003–2008Hypertension, 2011
- Adherence and persistence with taking medication to control high blood pressureJournal of the American Society of Hypertension, 2011
- Divergent Results Using Clinic and Ambulatory Blood PressuresHypertension, 2010
- Translational medicine: the antihypertensive effect of renal denervationAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2010
- Adherence to MedicationThe New England Journal of Medicine, 2005
- Hypertension in Adults Across the Age SpectrumJAMA, 2005
- Global burden of hypertension: analysis of worldwide dataThe Lancet, 2005
- Placebo-Controls in Short-Term Clinical Trials of HypertensionScience, 2001
- Differential Control of Systolic and Diastolic Blood PressureHypertension, 2000